Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | MIF | P14174 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7697156 | 0.98 | ALDH1A1 (0.45) | ALDH1A1ADRB2ADRB1ADRB3CES2 | |
| SCHEMBL27700166 | 0.91 | — | — | |
| SCHEMBL31249699 | 0.82 | GABRA5 (0.43) | ALDH1A1KMT2ASMN1; SMN2TSHRMEN1 | |
| SCHEMBL6350238 | 0.81 | ALDH1A1 (0.44) | ALDH1A1ADRB2ADRB1ADRB3CES2 | |
| Hydrochloric Acid SCHEMBL31249822 | 0.80 | GABRA5 (0.42) | ALDH1A1KMT2ASMN1; SMN2TSHRMEN1 | |
| SCHEMBL15443027 | 0.79 | ALDH1A1 (0.46) | ALDH1A1ADRB2ADRB1ADRB3CES2 | |
| SCHEMBL634058 | 0.79 | ALDH1A1 (0.46) | ALDH1A1ADRB2ADRB1ADRB3CES2 | |
| SCHEMBL15443392 | 0.79 | ALDH1A1 (0.46) | ALDH1A1ADRB2ADRB1ADRB3CES2 | |
| SCHEMBL4787371 | 0.79 | ALDH1A1 (0.47) | ALDH1A1ADRB2ADRB1ADRB3CES2 | |
| SCHEMBL15442983 | 0.79 | ALDH1A1 (0.46) | ALDH1A1ADRB2ADRB1ADRB3CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350311-B1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | MADRIGAL PHARMACEUTICALS INC (US) | 2013-12-25 | — | — | EP | claimed |
| US-8324385-B2 | Diacylglycerol acyltransferase inhibitors | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | claimed |
| EP-2350311-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | Via Pharmaceuticals, Inc. (US) | 2011-08-03 | — | — | EP | claimed |
| WO-2010056506-A1 | DIACYLGLYCEROL ACLYTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | claimed |
| US-20100113782-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2010-05-06 | — | — | US | claimed |
| US-8324385-B2 | Diacylglycerol acyltransferase inhibitors | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| EP-2350311-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | Via Pharmaceuticals, Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010056506-A1 | DIACYLGLYCEROL ACLYTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20100113782-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2010-05-06 | — | — | US | disclosed |
| EP-0612524-B1 | Angiotensin II antagonists for the treatment of viral diseases | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1998-08-26 | — | — | EP | disclosed |
| US-5750551-A | ANGIOTENSIN INHIBITORS, BENZIMIDAZOLE DERIVATIVES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-05-12 | — | — | US | disclosed |
| US-5605919-A | PREVENTION OF CELL INJURY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-02-25 | — | — | US | disclosed |
| EP-0612524-A1 | Angiotensin II antagonists for the treatment of viral diseases | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113782-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, MOGAT2 | ALDH1A1 802/4885ADRB2 2026/4885ADRB1 1716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.